Evidence map›Paper›PMID 41901277›Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones.

Jessica Ceramella, Annaluisa Mariconda, Domenico Iacopetta, Maria Marra, Alessia Catalano, Paola Checconi, Stefano Aquaro, Carmela Saturnino, Pasquale Longo, Maria Stefania Sinicropi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jessica CeramellaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.ORCID 0000-0002-1386-3601
Annaluisa MaricondaDepartment of Basic and Applied Sciences, University of Basilicata, Via dell'Ateneo Lucano, 10, 85100 Potenza, Italy.ORCID 0000-0002-9763-838X
Domenico IacopettaDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.ORCID 0000-0001-5179-7118
Maria MarraDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.
Alessia CatalanoDepartment of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Via Orabona, 4, 70126 Bari, Italy.ORCID 0000-0002-7420-4706
Paola ChecconiDepartment for the Promotion of Human Sciences and Quality of Life, San Raffaele University, Via di Val Cannuta 247, 00166 Rome, Italy.ORCID 0000-0001-7518-5730
Stefano AquaroDepartment of Life, Health and Environmental Sciences, University of L'Aquila, Piazzale Salvatore Tommasi, 1, Blocco 11, Coppito, 67010 L'Aquila, Italy.ORCID 0000-0002-8417-2103
Carmela SaturninoDepartment of Health Sciences, University of Basilicata, Via dell'Ateneo Lucano, 10, 85100 Potenza, Italy.ORCID 0000-0002-7419-8780
Pasquale LongoDepartment of Chemistry and Biology "A. Zambelli", University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.ORCID 0000-0002-7685-1093
Maria Stefania SinicropiDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.ORCID 0000-0003-2435-8931

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last three decades, 2-oxazolidinones have emerged as an important class of inhibitors of bacterial protein synthesis, effective in the treatment of multidrug-resistant (MDR) bacterial infections. From a public health perspective, the importance of 2-oxazolidinones is related to the treatment of tuberculosis (TB), primarily MDR-TB and extensively drug-resistant XDR-TB. Linezolid, the first oxazolidinone antibiotic approved by FDA, is still used in therapy despite common adverse events, such as myelosuppression and serotonergic toxicity, as well as the increasing percentage of linezolid-resistant bacteria (

Indexed as

antimicrobial resistancelinezolidmultidrug-resistant bacteriatedizolidtuberculosis

Identifiers

PMID41901277
PMCPMC13028916

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.